How did Steminent Biotherapeutics (7729.TWO) break into the Japanese market with its allogeneic stem cell therapy? 

In November 2024, Steminent became Taiwan’s first and Asia-Pacific’s first biotech company to receive Japan’s Foreign Manufacturer Accreditation for Regenerative Medical Products from the Ministry of Health, Labour and Welfare (MHLW). This marks a major milestone for Taiwan’s regenerative medicine industry on the global stage!

The company’s allogeneic adipose-derived mesenchymal stem cell (ADMSC) therapy, Stemchymal®, targets Spinocerebellar Ataxia (SCA) and is set to legally enter the Japanese market upon receiving Japan’s conditional approval.

With Japan ranking as the world’s third-largest healthcare market, this accreditation paves the way for Taiwan-Japan collaboration in R&D and manufacturing, advancing cell therapy innovations and expanding Taiwan’s biotech footprint in Japan. 

 Read more: http://bit.ly/v123industry1